These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

366 related items for PubMed ID: 10208832

  • 1. Effect of SB 217242 on hypoxia-induced cardiopulmonary changes in the high altitude-sensitive rat.
    Underwood DC, Bochnowicz S, Osborn RR, Luttmann MA, Louden CS, Hart TK, Elliott JD, Hay DW.
    Pulm Pharmacol Ther; 1999; 12(1):13-26. PubMed ID: 10208832
    [Abstract] [Full Text] [Related]

  • 2. Nonpeptide endothelin receptor antagonists. X. Inhibition of endothelin-1- and hypoxia-induced pulmonary pressor responses in the guinea pig by the endothelin receptor antagonist, SB 217242.
    Underwood DC, Bochnowicz S, Osborn RR, Luttmann MA, Hay DW.
    J Pharmacol Exp Ther; 1997 Dec; 283(3):1130-7. PubMed ID: 9399985
    [Abstract] [Full Text] [Related]

  • 3. Chronic hypoxia-induced cardiopulmonary changes in three rat strains: inhibition by the endothelin receptor antagonist SB 217242.
    Underwood DC, Bochnowicz S, Osborn RR, Louden CS, Hart TK, Ohlstein EH, Hay DW.
    J Cardiovasc Pharmacol; 1998 Dec; 31 Suppl 1():S453-5. PubMed ID: 9595510
    [Abstract] [Full Text] [Related]

  • 4. Nonpeptide endothelin receptor antagonists. VIII: attentuation of acute hypoxia-induced pulmonary hypertension in the dog.
    Willette RN, Ohlstein EH, Mitchell MP, Sauermelch CF, Beck GR, Luttmann MA, Hay DW.
    J Pharmacol Exp Ther; 1997 Feb; 280(2):695-701. PubMed ID: 9023281
    [Abstract] [Full Text] [Related]

  • 5. Endothelin receptors mediating contraction of rat and human pulmonary resistance arteries: effect of chronic hypoxia in the rat.
    McCulloch KM, Docherty C, MacLean MR.
    Br J Pharmacol; 1998 Apr; 123(8):1621-30. PubMed ID: 9605569
    [Abstract] [Full Text] [Related]

  • 6. Inhibition of endothelin-1 and hypoxia-induced pulmonary pressor responses in the rat by a novel selective endothelin-A receptor antagonist, di-n-butylaminocarbamyl-L-leucyl-D-tryptophanyl-D-4-chloro-Phe.
    Yan LD, Kong LL, Yong Z, Dong HJ, Chi MG, Pan XF, Zhang C, Liang YJ, Gong ZH, Liu KL.
    J Cardiovasc Pharmacol; 2010 Sep; 56(3):246-54. PubMed ID: 20531217
    [Abstract] [Full Text] [Related]

  • 7. Endothelin in the pulmonary circulation with special reference to hypoxic pulmonary vasoconstriction.
    Holm P.
    Scand Cardiovasc J Suppl; 1997 Sep; 46():1-40. PubMed ID: 9265559
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Nonpeptide endothelin receptor antagonists. VI: Pharmacological characterization of SB 217242, a potent and highly bioavailable endothelin receptor antagonist.
    Ohlstein EH, Nambi P, Lago A, Hay DW, Beck G, Fong KL, Eddy EP, Smith P, Ellens H, Elliott JD.
    J Pharmacol Exp Ther; 1996 Feb; 276(2):609-15. PubMed ID: 8632328
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. ZD1611, an orally active endothelin-A receptor antagonist, prevents chronic hypoxia-induced pulmonary hypertension in the rat.
    Bialecki RA, Fisher CS, Abbott BM, Barthlow HG, Caccese RG, Stow RB, Rumsey J, Rumsey W.
    Pulm Pharmacol Ther; 1999 Feb; 12(5):303-12. PubMed ID: 10545286
    [Abstract] [Full Text] [Related]

  • 12. The orally active nonpeptide endothelin A-receptor antagonist A-127722 prevents and reverses hypoxia-induced pulmonary hypertension and pulmonary vascular remodeling in Sprague-Dawley rats.
    Chen SJ, Chen YF, Opgenorth TJ, Wessale JL, Meng QC, Durand J, DiCarlo VS, Oparil S.
    J Cardiovasc Pharmacol; 1997 Jun; 29(6):713-25. PubMed ID: 9234651
    [Abstract] [Full Text] [Related]

  • 13. Effect of novel mixed ETA/ETB antagonists on responses to ET-1 in human small muscular pulmonary arteries.
    MacLean MR, Docherty CC, McCulloch KM, Morecroft I.
    Pulm Pharmacol Ther; 1998 Jun; 11(2-3):147-9. PubMed ID: 9918747
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. TBC3711, an ET(A) receptor antagonist, reduces neonatal hypoxia-induced pulmonary hypertension in piglets.
    Perreault T, Berkenbosch JW, Barrington KJ, Decker ER, Wu C, Brock TA, Baribeau J.
    Pediatr Res; 2001 Sep; 50(3):374-83. PubMed ID: 11518825
    [Abstract] [Full Text] [Related]

  • 16. Glibenclamide reveals role for endothelin in hypoxia-induced vasoconstriction in rat intrapulmonary arteries.
    López-Valverde V, Andersen CU, Laursen BE, Mulvany MJ, Simonsen U.
    J Cardiovasc Pharmacol; 2005 Oct; 46(4):422-9. PubMed ID: 16160592
    [Abstract] [Full Text] [Related]

  • 17. The effect of the ETA receptor antagonist (CI-1020) in rats with established hypoxic pulmonary hypertension.
    Sheedy W, Haleen S, Morice AH.
    Pulm Pharmacol Ther; 1998 Oct; 11(2-3):173-6. PubMed ID: 9918751
    [Abstract] [Full Text] [Related]

  • 18. [Effects of endothelin receptor antagonist on the hypoxic pulmonary hypertension].
    Chen W, Cheng D.
    Hua Xi Yi Ke Da Xue Xue Bao; 2000 Sep; 31(3):370-2, 386. PubMed ID: 12545837
    [Abstract] [Full Text] [Related]

  • 19. Contribution of endogenous endothelin-1 to the progression of cardiopulmonary alterations in rats with monocrotaline-induced pulmonary hypertension.
    Miyauchi T, Yorikane R, Sakai S, Sakurai T, Okada M, Nishikibe M, Yano M, Yamaguchi I, Sugishita Y, Goto K.
    Circ Res; 1993 Nov; 73(5):887-97. PubMed ID: 8403258
    [Abstract] [Full Text] [Related]

  • 20. Plasma- and cerebrospinal fluid-immunoreactive endothelin-1: effects of nonpeptide endothelin receptor antagonists with diverse affinity profiles for endothelin-A and endothelin-B receptors.
    Willette RN, Sauermelch CF, Storer BL, Guiney S, Luengo JI, Xiang JN, Elliott JD, Ohlstein EH.
    J Cardiovasc Pharmacol; 1998 Nov; 31 Suppl 1():S149-57. PubMed ID: 9595425
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.